Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout

 
• By Joseph Haas
  
Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Blueprint's buyout of Lengo adds a third NSCLC drug candidate

More from Deals

More from Business